CaitlinLCostelloMD

PubMed

• 3 citations
  Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN.
  Ajai Chari, Jonathan L Kaufman, Jacob Laubach, Douglas W Sborov, Brandi Reeves
  Blood Cancer Journal. 2024-07-08
• A CD10-negative adult B-lymphoblastic leukaemia with amplification of KMT2A without rearrangement: A case report and review of the English literature.
  Huan-You Wang, Hailee M St Louis, Caitlin L Costello, Sarah S Murray, Marie L Dell'Aquila
  British Journal of Haematology. 2024-07-01
• Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethas...
  Rebecca Silbermann, Jacob Laubach, Jonathan L Kaufman, Douglas W Sborov, Brandi Reeves
  American Journal of Hematology. 2024-07-01

Journal Articles

• Immunotherapy in Multiple Myeloma  
  Costello C, J Hematol Mult Myeloma, 1/1/2016
• Multiple Myeloma, Version 22016  
  Anderson KC, Alsina M, Atanackovic D, Biermann JC, Chandler JC, Costello C, Bjulbegovic B, Fung HC, Gasparetto C, Godby K, Hofmeister C, Holmberg L, Holstein S, Huff C..., J Natl Compr Canc Netw, 1/1/2015

Abstracts/Posters

• Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Blinatumomab/Lenalidomide in Relapsed/Refractory Non-HodgkinÍs Lymphoma: A Phase I California Cancer Consortium Study of Safety, Efficacy and Immune Correlative Analysis
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Real-World (RW) Multiple Myeloma (MM) Patients (Pts) Remain Under-Represented in Clinical Trials Based on Standard Laboratory Parameters and Baseline Characteristics: ...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Closing the Efficacy and Effectiveness Gap: Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Patients (Pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IR...
  Caitlin L. Costello, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study.
  Rifkin RM, Davies FE, Palumo A, Zonder J, Girnius SK, Costello CL, Usmani SZ, Berdeja JG, Omel J, Thompson MA, Schwartz JS, Hajek R, Terpos E, Hungria V, Mateos MV, Co..., International Myeloma Working Group XVI, New Delhi, India, 1/1/2017
• Aberrant RNA Editing of GLI1 Promotes Malignant Regeneration in Multiple Myeloma. [abstract].
  Lazzari E, Delos Santos NP, Wu C, Leu H, Pineda G, Ali S, Costello C, Minden M, Chiaramonte R, Crews LA, Jamieson C, AACR; Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, Washington, DC, 1/1/2017
• ADAR1-dependent RNA editing is a mechanism of therapeutic resistance in human plasma cell malignancies.
  Lazzari E, Crews LA, Wu C, Leu H, Ali S, Chiaramonte R, Minden M, Costello C, Jamieson C, Cancer Res; Proceedings of the 107th Annual Meeting of the American Association for Cancer Research, New Orleans, LA, 1/16/2016
• Next Generation Sequencing Reveals Potentially Actionable Alterations in the Majority of Patients with Lymphoid Malignancies.
  Goodman, AM, Choi MY, Wieduwilt MJ, Mulroney CM, Costello CL, Kurzrock R, Blood, 1/1/2016
• Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study.
  Rifkin RM, Davies FE, Palumo A, Zonder J, Girnius SK, Costello CL, Usmani SZ, Berdeja JG, Omel J, Thompson MA, Shah J, Schwartz JS, Hajek R, Terpos E, Hungria V, Mateo..., Blood, 1/1/2016
• Updated results of a multicenter phaseI/Ib study of CTLA blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplanta...
  Davids, MS, Haesook TK, Costello C, et al, Haematologica; European Hematology Association, Vienna, Austria, 1/1/2015
• A Multicenter Phase I/Ib Study of Ipilimumab for Relapsed Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation.
  Davids, MS, Kim, Haesook T, Costello C, et al, Blood, 1/1/2015
• Targeting Cancer Stem Cell Survival in Plasma Cell Leukemia with a Pan-BCL2 Inhibitor.
  Lazzari E, Crews LA, Wu C, Leu H, Chiaramonte R, Minden MD, Costello C, Jamieson C, Blood, 1/1/2015
• Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: results from a multicenter phase 2 Trial.
  Richardson PG, Bensinger WI, Huff CA, Costello C, et al, Clinical Lymphoma, Myeloma & Leukemia, 1/1/2015
• Ibrutinib in combination with low-dose dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma; results from a multicenter phase 2 trial.
  Richardson, PG, Bensinger WI, Huff CA, Costello C, et al, International Myeloma Working Group Workshop – XV, Rome, Italy, 1/1/2015
• Interim results of a multicenter phase I/Ib study of CTLA4 blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplan...
  Davids, MS, Haesook TK, Costello C, et al, 41st Annual Meeting of the European Society for Blood and Marrow Transplantation, Istanbul, Turkey, 1/1/2015
• Ibrutinib, Single Agent or in Combination with Dexamethasone, in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma: Preliminary Phase 2 Results.
  Vij R, Huff CA, Bensinger WI, Siegel DS, Jagannath S, Berdeja JG, Lendvai N, Lebovic D, Anderson LD, Costello C, et al, 56th ASH Annual Meeting and Exposition, San Francisco, CA, 1/1/2014
• A multicenter Phase 1 of CTLA blockade with Ipilimumab for Relapsed Hematologic Malignancies after allogeneic Hematopoietic Cell Transplantation.
  Davids MS, Haesook TK, Costello C et al, 56th ASH Annual Meeting and Exposition, San Francisco, CA, 1/1/2014
• Multiple Myeloma in Patients Under 40 Years Old is Associated with High-Risk Features and Worse Outcomes.
  Costello C, Blood; ASH Annual Meeting, 1/1/2013
• Impact of Deletion 17p on the Outcome of Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
  Costello C, Corringham S, Li H, Messer K, Ball ED, Blood; ASH Annual Meeting, 1/1/2012
• A Planned Phase I/IB Study of Ipilimumab in Relapsed Hematologic Malignancies After Allo-HCT.
  Davids MS, Bashey A, Costello C, et al, 2nd International Workshop in the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, NIH, Bethesda, MD, 1/1/2012
• Idiotype Immunization Following High-Dose Therapy and Autologous Stem Cell Transplantation for Non-Hodgkin Lymphoma.
  Costello C, Holman PR, Demagalhaes-Silverman M, Corringham S, Castro J, Ball ED, Blood; ASH Annual Meeting, 1/1/2011
• Join now to see all

Lectures

• Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa... 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Phase 2 Study of the Response and Safety of P-Bcma-101 CAR-T Cells in Patients with Relapsed/Refractory (r/r) Multiple Myeloma (MM) (PRIME)Clinically Relevant Abstract 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Genetic Modulation of Adenosine-to-Inosine RNA Editing Selectively Disrupts Inflammasome and Extracellular Matrix Genes in Multiple Myeloma 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Ixazomib Plus Lenalidomide-Dexamethasone (IRd) in Relapsed/Refractory Multiple Myeloma (MM) Patients (Pts) – Effectiveness in Routine Clinical Practice Is Similar to t... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Plasma Cell Disorders, Myeloma 
  Brisbane, Australia - 1/1/2016
• Treatment of Relapsed/Refractory Multiple Myeloma 
  San Francisco, CA - 1/1/2016
• Myeloma and the Ever-Complicated Immune System 
  La Jolla, CA - 1/1/2015
• Multiple Myeloma: The Basics and Beyond 
  San Diego, CA - 1/1/2015
• Myeloma: The Basics 
  La Jolla, CA - 1/1/2014
• Oncologic Emergencies 
  San Diego, CA - 1/1/2013
• Multiple Myeloma: What’s new in 2012 
  La Jolla, CA - 1/1/2012
• Join now to see all

Other

• Managing neutropenic fever in oncology patients. 
  Wooten D, Chang W, Costello C, ACP Hospitalist
  1/1/2016
• Oncologic Emergencies and the Family Physician. 
  Costello C, Maryland Family Doctor, Spring
  1/1/2014